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INTRODUCTION
We present a case of severe fungal infection of the cornea in which
systemic oral voriconazole was used as an adjunct therapy after conventio-
nal antifungal medical therapy failure. This case report may warrant additio-
nal investigation on the role of this anti-fungal agent to treat severe myco-
tic corneal infection.
CASE REPORT
A 40-year-old man presented with history of corneal ulcer treatment in
the left eye in the previous week: Tobradex® (0.3% tobramycin - 3 mg, 0.1%
dexamethasone - 1 mg, and 0.01% benzalkonium chloride preservative) and
Maxitrol® (polymyxin B sulfate, neomycin sulfate, and 0.1% dexamethasone
- 1 mg) drops. This regimen was ineffective and the patient was referred to
a second opinion.
At presentation, visual acuity was normal (20/20) in the right eye and
20/200 in the left eye. There was slight lid edema and moderate conjunctival
and pericorneal injection. A corneal epithelial defect measuring 2 x 2 mm
with an infiltrate (abscess) was observed, surrounded by a small amount of
stromal edema, with a small amount of mucopurulent material covering the
base of the ulcer and at the inferior fornix. The ulcer had a deep central
ulceration and the abscess with indistinct margins involving the paracen-
tral corneal zone. There was anterior chamber reaction (1+/4+) and a discre-
te hypopyon of 0.5 mm in height. Lens and fundus examinations were
normal (Figure 1).
The patient denied any trauma, systemic disease or use of contact lens.
Specimens were collected by scraping the margin of the abscess and bed of
the corneal ulcer, which were submitted to bacteriological and mycological
analysis. Scrapings were inoculated onto blood agar, brain heart infusion
(BHI) and Sabouraud agar. Gram stain showed gram-positive cocci. Further
results did not identify any culture growth.
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As suggested by the gram stain, the patient was treated
initially with fortified antibiotics (50 mg/ml cefazolin and 1 mg/ml
amicacin) and fourth generation fluoroquinolone (gatifloxa-
cin) hourly. Dilating drops (1% ciclopentolate) every eight
hours were also instituted. The patient was examined every
day. As time went by, the corneal condition seemed to impro-
ve slightly and treatment with 1% dexametasone twice daily to
decrease the inflammation of the eye. However, by day 12 of
treatment (5 days on corticosteroid), the infiltrate seemed to
be growing in extension and some adjacent whitish lesions
(satellite lesions) were observed which led to the suspicion of
fungal infection (Figure 2).
Corticosteroid treatment was discontinued immediately
and the patient started on 0.15% amphotericin B and 5% nata-
micin drops hourly and oral ketoconazole (200 mg twice daily).
It is worth noting that at that time, laboratory results had not
yielded any culture growth and the treatment was based on
the history told by the patient (abrupt onset of symptoms),
clinical aspects (compatible with bacterial ulcer) and the gram
stain (also compatible with bacterial infection). Despite this
regimen of treatment, the aspect of the cornea had not impro-
ved and it was actually enlarged (Figure 3).
As the cornea worsened, another scraping was performed
for further analysis. At the same time, a corneal biopsy was
also performed. The laboratory results revealed filamentous
fungal infection (Aspergillus flavus). In three days, infiltra-
tion of the cornea and the hypopyon had greatly increased.
Intracameral amphotericin B (10 micrograms) was employed
twice. It has been shown that intracameral amphotericin B
does not cause corneal or lenticular toxicity and it has been
used with success in anecdotal cases of Aspergillus flavus
keratitis(1). Despite this procedure, the infiltrate extended to
the limbus and the cornea started to melt (Figure 4).
Oral voriconazole was initiated (200 mg p.o. daily). In face
of an impending perforation, cornea transplantation was per-
formed (Figures 5 and 6). Although the cornea the Eye Bank
released was meant to be for a tectonic transplantation, the
graft remained clear and with no signs of either infection or
rejection, more that 2 months after the corneal transplantation.
Initially, the patient was kept on topical cyclosporine twice
daily (Restasis®), due to the fact that corticosteroids were kept
until there were no signs of fungal relapse.
As time passed and there was no sign of fungal infection
remission, low-dose corticosteroid was initiated to minimize
eye inflammation. Alrex® twice daily was started (for 1 week)
then switched to Loteprol® twice daily (for 1 week). After there
was confidence that there was no infection, Minidex® twice
daily was initiated (for 1 week) and then switched to Maxidex®
Figure 1 - A 2x2 mm corneal epithelial defect with abscess and a
stromal edema, mucopurulent material covering the base of the ulcer.
The ulcer had a deep central ulceration and the abscess showed
indistinct margins involving the paracentral corneal zone. There was
anterior chamber reaction and a discrete hypopyon of 0.5 mm in height.
Figure 2 - After five days on corticosteroid, the infiltrate extension
increased and some adjacent whitish lesions (satellite lesions) that
raised the suspicion of fungal infection were observed
Figure 3 - Despite the treatment, the aspect of the cornea had not im-
proved and the ulcer had enlarged
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twice a day. The patient has been kept on this regimen for 2
weeks and cyclosporine has been discontinued.
On the last visit, three months after the corneal transplan-
tation, the graft remained clear and the best corrected visual
acuity with contact lenses was 20/30, though we do not yet
intend to fit them. We expect to start fitting contact lens after
at least 12 months of clear graft.
DISCUSSION
Fungal corneal infection is a vision-threatening condition
that may present in a challenging way. It has been demonstra-
ted that the use of topical corticosteroid may predispose to
the onset and the worsening of the fungal infection of the eye.
Despite aggressive treatment, the here described patient, was
irresponsive to the medical therapy.
Filamentous fungi are more common in patients with a
history of trauma of the eye, especially with vegetal material.
More rarely, Aspergillus flavus may cause severe infection of
the cornea after laser in situ keratomileusis(2). It has been
shown that intracameral amphotericin B does not cause cor-
neal or lenticular toxicity and has been used with success in
anecdotal cases of Aspergillus flavus keratitis(1). On the other
hand, patients with previous use of corticosteroid are more
prone to Candida-like infections.
The drugs available to treat infections of the eye with
fungi are limited. Moreover, their penetration into the eye is
limited. The case of a fungal corneal infection treated with a
new antifungal agent (voriconazole) with very good result is
reported in this article.
Searching the medical literature, a paper reporting the use of
oral voriconazole with great success was found, though in this
case it was not a keratomycosis caused by Aspergillus flavus(3).
A study by Hariprasad(4) demonstrated that orally admi-
nistered voriconazole reaches therapeutic aqueous and vi-
treous levels in the noninflamed human eye and that the
activity spectrum appears appropriately to encompass the
most frequent encountered mycotic species involved in the
various causes of fungal eye infection.
We considered that oral voriconazole might be important
in attempting to prevent further spread of the fungus to the
interior of the eye, since the transplantation of the cornea
alone would not have been sufficient to keep the fungus in the
anterior portion of the eye, because the periphery of the cor-
nea was already compromised and Descemet’s membrane had
been breached.
Some papers demonstrated in the aqueous a concentration
more than 50% than that in plasma and almost seven times
higher than the MIC for Scedosporium apiospermum strain.
Hua et at(5) demonstrated that intravitreal voriconazole of up
to 25 microgram/ml causes no ERG change or histologic
abnormality in rat retina. This may indicate that voriconazole
Figure 4 - The infiltrate extended to the limbus and the cornea started
to melt
Figure 6 - In face of an impending perforation, a cornea transplantation
was performed
Figure 5 - Cornea with an impending perforation
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is a safe antifungal agent that may be employed by intravitreal
injection in the treatment of fungal infections of the eye.
We could not find any study on the topical concentration
of cyclosporine used in this case (0.05%), although higher
doses have shown to be of some clinical effectiveness(6).
CONCLUSIONS
This case report shows that severe fungal eye infections
may benefit from the use of adjunct systemic voriconazole.
Further studies on animal models may determine the appro-
priate timing and dose of this promising drug.
RESUMO
O presente trabalho descreve o emprego do voriconazol sistê-
mico como adjuvante no tratamento de ceratite micótica grave
por Aspergillus flavus.
Descritores: Fluconazol/uso terapêutico; Infecções oculares
fúngicas/quimioterapia; Ceratite; Antimicóticos/uso terapêu-
tico; Relatos de casos [tipo de publicação]
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